Anaveon AG

The Swiss biotech industry achieved record revenues and attracted impressive private financing rounds as immunology products came to the fore, new research shows. Chocolate may be the first product th

One of the leading contenders to improve on interleukin-2 (IL-2)-based therapy in oncology is down and possibly out as Nektar Therapeutics and Bristol Myers Squibb Company announced the failure of

Big backing for venture capital-funded private biopharmaceutical companies has not wavered as 2021 draws to a close despite a recent slowdown in large initial public offerings by drug developers in th

Four and a half years after its foundation, Swiss biotech Anaveon has begun clinical testing of its powerful and selective interleukin-2 agonist, to assess its potential as a safer, more specific in